PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling-Reference-Cited by-同舟云学术

PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling

Published:2013-07 Issue:7 Volume:20 Page:912-921
ISSN:1074-5521
Container-title:Chemistry & Biology
language:en
Short-container-title:Chemistry & Biology

Author:

Cai Xinming,Xu Yongyao,Cheung Atwood K.,Tomlinson Ronald C.,Alcázar-Román Abel,Murphy Leon,Billich Andreas,Zhang Bailin,Feng Yan,Klumpp Martin,Rondeau Jean-Michel,Fazal Aleem N.,Wilson Christopher J.,Myer Vic,Joberty Gerard,Bouwmeester Tewis,Labow Mark A.,Finan Peter M.,Porter Jeffrey A.,Ploegh Hidde L.,Baird Daniel,De Camilli Pietro,Tallarico John A.,Huang Qian

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,General Medicine,Biochemistry

Reference44 articles.

1. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease;Abraham;Annu. Rev. Med.,2009

2. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency;Billich;IDrugs,2007

3. A mammalian protein targeted by G1-arresting rapamycin-receptor complex;Brown;Nature,1994

4. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease;Burakoff;Inflamm. Bowel. Dis.,2006

5. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway;Cao;Nat. Immunol.,2008

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The erlin1/erlin2 complex binds to and stabilizes phosphatidylinositol 3-phosphate and regulates autophagy;Biochemical and Biophysical Research Communications;2024-10

2. A PIKfyve modulator combined with an integrated stress response inhibitor to treat lysosomal storage diseases;Proceedings of the National Academy of Sciences;2024-08-16

3. Novel Therapies for ANCA-associated Vasculitis: Apilimod Ameliorated Endothelial Cells Injury through TLR4/NF-κB Pathway and NLRP3 Inflammasome;Current Pharmaceutical Design;2024-08

4. PIKfyve, expressed by CD11c-positive cells, controls tumor immunity;Nature Communications;2024-06-28

5. Selective Termination of Autophagy-Dependent Cancers;Cells;2024-06-25